# Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

> **NCT02344407** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1500 (actual)

## Conditions studied

- Ebola Virus

## Interventions

- **BIOLOGICAL:** VSVG-ZEBOV
- **BIOLOGICAL:** ChAd3-EBO Z
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02344407
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2016-06-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344407, "Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02344407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*